These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 25630040)

  • 1. Passive transfer of neutralizing mAb KD-247 reduces plasma viral load in patients chronically infected with HIV-1.
    Matsushita S; Yoshimura K; Ramirez KP; Pisupati J; Murakami T;
    AIDS; 2015 Feb; 29(4):453-62. PubMed ID: 25630040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postinfection passive transfer of KD-247 protects against simian/human immunodeficiency virus-induced CD4+ T-cell loss in macaque lymphoid tissue.
    Murakami T; Eda Y; Nakasone T; Ami Y; Someya K; Yoshino N; Kaizu M; Izumi Y; Matsui H; Shinohara K; Yamamoto N; Honda M
    AIDS; 2009 Jul; 23(12):1485-94. PubMed ID: 19528788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial.
    Stephenson KE; Julg B; Tan CS; Zash R; Walsh SR; Rolle CP; Monczor AN; Lupo S; Gelderblom HC; Ansel JL; Kanjilal DG; Maxfield LF; Nkolola J; Borducchi EN; Abbink P; Liu J; Peter L; Chandrashekar A; Nityanandam R; Lin Z; Setaro A; Sapiente J; Chen Z; Sunner L; Cassidy T; Bennett C; Sato A; Mayer B; Perelson AS; deCamp A; Priddy FH; Wagh K; Giorgi EE; Yates NL; Arduino RC; DeJesus E; Tomaras GD; Seaman MS; Korber B; Barouch DH
    Nat Med; 2021 Oct; 27(10):1718-1724. PubMed ID: 34621054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of the susceptibility of HIV-1 to a neutralizing antibody KD-247 by nonepitope mutations distant from its epitope.
    Takizawa M; Miyauchi K; Urano E; Kusagawa S; Kitamura K; Naganawa S; Murakami T; Honda M; Yamamoto N; Komano J
    AIDS; 2011 Nov; 25(18):2209-16. PubMed ID: 21866041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117.
    Caskey M; Klein F; Lorenzi JC; Seaman MS; West AP; Buckley N; Kremer G; Nogueira L; Braunschweig M; Scheid JF; Horwitz JA; Shimeliovich I; Ben-Avraham S; Witmer-Pack M; Platten M; Lehmann C; Burke LA; Hawthorne T; Gorelick RJ; Walker BD; Keler T; Gulick RM; Fätkenheuer G; Schlesinger SJ; Nussenzweig MC
    Nature; 2015 Jun; 522(7557):487-91. PubMed ID: 25855300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate.
    Shibata J; Yoshimura K; Honda A; Koito A; Murakami T; Matsushita S
    J Virol; 2007 Apr; 81(8):3757-68. PubMed ID: 17251298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
    Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR
    J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance profile of a neutralizing anti-HIV monoclonal antibody, KD-247, that shows favourable synergism with anti-CCR5 inhibitors.
    Yoshimura K; Shibata J; Kimura T; Honda A; Maeda Y; Koito A; Murakami T; Mitsuya H; Matsushita S
    AIDS; 2006 Oct; 20(16):2065-73. PubMed ID: 17053352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human immunodeficiency virus type 1 evasion of a neutralizing anti-V3 antibody involves acquisition of a potential glycosylation site in V2.
    Hatada M; Yoshimura K; Harada S; Kawanami Y; Shibata J; Matsushita S
    J Gen Virol; 2010 May; 91(Pt 5):1335-45. PubMed ID: 20032207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ex vivo neutralization of HIV-1 quasi-species by a broadly reactive humanized monoclonal antibody KD-247.
    Matsushita S; Takahama S; Shibata J; Kimura T; Shiozaki K; Eda Y; Koito A; Murakami T; Yoshimura K
    Hum Antibodies; 2005; 14(3-4):81-8. PubMed ID: 16720978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination anti-HIV antibodies provide sustained virological suppression.
    Sneller MC; Blazkova J; Justement JS; Shi V; Kennedy BD; Gittens K; Tolstenko J; McCormack G; Whitehead EJ; Schneck RF; Proschan MA; Benko E; Kovacs C; Oguz C; Seaman MS; Caskey M; Nussenzweig MC; Fauci AS; Moir S; Chun TW
    Nature; 2022 Jun; 606(7913):375-381. PubMed ID: 35650437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of a human monoclonal antibody directed against the CD4-binding site of HIV type 1 glycoprotein 120.
    Cavacini LA; Samore MH; Gambertoglio J; Jackson B; Duval M; Wisnewski A; Hammer S; Koziel C; Trapnell C; Posner MR
    AIDS Res Hum Retroviruses; 1998 May; 14(7):545-50. PubMed ID: 9591708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-V3 humanized antibody KD-247 effectively suppresses ex vivo generation of human immunodeficiency virus type 1 and affords sterile protection of monkeys against a heterologous simian/human immunodeficiency virus infection.
    Eda Y; Murakami T; Ami Y; Nakasone T; Takizawa M; Someya K; Kaizu M; Izumi Y; Yoshino N; Matsushita S; Higuchi H; Matsui H; Shinohara K; Takeuchi H; Koyanagi Y; Yamamoto N; Honda M
    J Virol; 2006 Jun; 80(11):5563-70. PubMed ID: 16699037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two neutralizing anti-V3 monoclonal antibodies act by affecting different functions of human immunodeficiency virus type 1.
    Armstrong SJ; McInerney TL; McLain L; Wahren B; Hinkula J; Levi M; Dimmock NJ
    J Gen Virol; 1996 Dec; 77 ( Pt 12)():2931-41. PubMed ID: 9000083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody 10-1074 suppresses viremia in HIV-1-infected individuals.
    Caskey M; Schoofs T; Gruell H; Settler A; Karagounis T; Kreider EF; Murrell B; Pfeifer N; Nogueira L; Oliveira TY; Learn GH; Cohen YZ; Lehmann C; Gillor D; Shimeliovich I; Unson-O'Brien C; Weiland D; Robles A; Kümmerle T; Wyen C; Levin R; Witmer-Pack M; Eren K; Ignacio C; Kiss S; West AP; Mouquet H; Zingman BS; Gulick RM; Keler T; Bjorkman PJ; Seaman MS; Hahn BH; Fätkenheuer G; Schlesinger SJ; Nussenzweig MC; Klein F
    Nat Med; 2017 Feb; 23(2):185-191. PubMed ID: 28092665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complementary and synergistic activities of anti-V3, CD4bs and CD4i antibodies derived from a single individual can cover a wide range of HIV-1 strains.
    Ramirez Valdez KP; Kuwata T; Maruta Y; Tanaka K; Alam M; Yoshimura K; Matsushita S
    Virology; 2015 Jan; 475():187-203. PubMed ID: 25486586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralizing antibody response during human immunodeficiency virus type 1 infection: type and group specificity and viral escape.
    Arendrup M; Sönnerborg A; Svennerholm B; Akerblom L; Nielsen C; Clausen H; Olofsson S; Nielsen JO; Hansen JE
    J Gen Virol; 1993 May; 74 ( Pt 5)():855-63. PubMed ID: 7684062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial.
    Mayer KH; Seaton KE; Huang Y; Grunenberg N; Isaacs A; Allen M; Ledgerwood JE; Frank I; Sobieszczyk ME; Baden LR; Rodriguez B; Van Tieu H; Tomaras GD; Deal A; Goodman D; Bailer RT; Ferrari G; Jensen R; Hural J; Graham BS; Mascola JR; Corey L; Montefiori DC; ;
    PLoS Med; 2017 Nov; 14(11):e1002435. PubMed ID: 29136037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection.
    Lynch RM; Boritz E; Coates EE; DeZure A; Madden P; Costner P; Enama ME; Plummer S; Holman L; Hendel CS; Gordon I; Casazza J; Conan-Cibotti M; Migueles SA; Tressler R; Bailer RT; McDermott A; Narpala S; O'Dell S; Wolf G; Lifson JD; Freemire BA; Gorelick RJ; Pandey JP; Mohan S; Chomont N; Fromentin R; Chun TW; Fauci AS; Schwartz RM; Koup RA; Douek DC; Hu Z; Capparelli E; Graham BS; Mascola JR; Ledgerwood JE;
    Sci Transl Med; 2015 Dec; 7(319):319ra206. PubMed ID: 26702094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo.
    Lu CL; Murakowski DK; Bournazos S; Schoofs T; Sarkar D; Halper-Stromberg A; Horwitz JA; Nogueira L; Golijanin J; Gazumyan A; Ravetch JV; Caskey M; Chakraborty AK; Nussenzweig MC
    Science; 2016 May; 352(6288):1001-4. PubMed ID: 27199430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.